A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma

NCT05193214 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Sarcoma, Soft Tissue

Interventions

DRUG: Recombinant anti-PD-1 humanized monoclonal antibody injection

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.